IMPROVE Bleeding Risk Score
iatroX editorial team · Updated · Record checked · editorial policy
The IMPROVE Bleeding Risk Score estimates the risk of major bleeding in acutely ill medical inpatients, helping clinicians decide whether the benefit of pharmacologic VTE prophylaxis outweighs the bleeding risk.
inputs
evidence
derivation
Developed by Decousus et al. (Chest 2011) from the IMPROVE multinational registry of 15,156 acutely ill medical patients.
validation
Major bleeding occurred in 3.2% of high-risk (≥7) vs 1.5% of low-risk (<7) patients. The score has been validated in subsequent cohorts and is referenced in ACCP/CHEST VTE prevention guidelines.
guideline endorsements
ACCP/CHEST 2012 Antithrombotic Guidelines reference IMPROVE for bleeding risk assessment. ASH 2019 VTE prevention guidelines acknowledge bleeding risk assessment as integral to prophylaxis decisions.
references
- Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79.PMID: 20453069
- Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: ACCP Guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.PMID: 22315261